Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD – A randomised, double-blind, parallel group, multicenter, phase IIa pilot study – - SB010-COPD

Trial Profile

Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD – A randomised, double-blind, parallel group, multicenter, phase IIa pilot study – - SB010-COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Anti-GATA3 gene-therapy (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms SB010-COPD
  • Most Recent Events

    • 11 Sep 2017 According to a Sterna biologicals media release, data will be presented at the European Respiratory Society (ERS) Congress 2017.
    • 11 Sep 2017 Results published in a Sterna biologicals Media Release.
    • 11 Sep 2017 Primary endpoint (Between 10 and 25% of COPD patients have elevated eosinophils in the airways) has been met, according to a Sterna biologicals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top